Immunotherapy has fundamentally changed the treatment landscape for many patients with
cancer. mAbs targeting programmed cell death-1 (PD-1), programmed cell death ligand-1 …

Non-small-cell lung cancer (NSCLC) has become a paradigm of precision medicine, with
the discovery of numerous disease subtypes defined by specific oncogenic driver mutations …

Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …

Immunotherapy is one of the methods that can change the survival rate of patients with
malignant tumors, in addition to surgery therapy, radiotherapy, chemotherapy and targeted …

Lung cancer is a major global health problem. Several strategies are required to conquer
this cancer. Stricter implementations of tobacco control measures are necessary. Early …

Simple Summary Immuno-oncology has redefined the treatment of lung cancer, with the
ultimate goal being the reactivation of the anti-tumor immune response. This has led to the …

A deeper understanding of the key role of the immune system in regulating tumor growth
and progression has led to the development of a number of immunotherapies, including …

Therapies targeting immune checkpoints have recently shown encouraging activity in
patients with heavily pretreated advanced non–small cell lung cancer (NSCLC) …

Introduction Exploratory analysis of clinical trials in various tumor types have demonstrated
potential improvements in overall response rate (ORR) to chemotherapy after exposure to …

Recent advances in the understanding of immunology and antitumor immune responses
have led to the development of new immunotherapies, including vaccination approaches …